We are an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life-changing treatments for severe lung diseases. Embedded in our approach is the determination to find solutions for conditions which have an enormous deleterious impact on patients and their families and to transform the lives of those affected.
Patients with severe lung diseases can suffer from progressive difficulty in breathing and a relentless deterioration in quality of life. Receiving such a diagnosis can be devastating, due to the poor prognosis. We appreciate that living with such diseases presents a constant challenge, not only for patients but also for their families and caregivers. Our research and drug development programmes are specifically aimed at alleviating these challenges with the patient at the forefront of our minds.
2000
Served areaWorldwide
HeadquartersKronhusgatan 11, 41105 Gรถteborg โ Sweden
71,850,000
IPOSept. 27, 2019
Stock exchange(s)Nasdaq Stockholm